Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Discovery of Akt and its Role in Human Cell

4.3 Structure of Akt

4.4 Key Drivers

4.4.1 Increasing Focus of the Key Players on the Development of Akt Inhibitors

4.4.2 Technological Advancements in Drug Development

4.4.3 Positive Clinical Results

4.5 Key Barriers

4.5.1 Adverse Effect of Various Therapies

4.6 Akt/PKB Inhibitor Pipeline Analysis

4.6.1 Pipeline Analysis by Phase

4.6.2 Pipeline Analysis by Molecule Type

4.6.3 Pipeline Analysis by Route of Administration

4.6.4 Pipeline Analysis by Company

Chapter 5. Akt/PKB Inhibitors Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 Ipatasertib

5.1.1.1 Clinical trials

5.1.1.2 Clinical trial results

5.1.2 Enzastaurin

5.1.2.1 Clinical trials

5.1.2.2 Strategic development

5.1.2.3 Designation

5.1.2.4 Technology

5.2 Phase II

5.2.1 Capivasertib

5.2.1.1 Clinical trials

5.2.1.2 Clinical trial results

5.2.1.3 Technology

5.2.2 LY3023414

5.2.2.1 Clinical trials

5.2.2.2 Clinical trial results

5.2.2.3 Strategic development

5.2.3 MK-2206

5.2.3.1 Pre-Clinical study

5.2.3.2 Clinical trials

5.2.3.3 Clinical trial results

5.2.3.4 Strategic development

5.2.4 RX-0201

5.2.4.1 Clinical trials

5.2.4.2 Clinical trial results

5.2.4.3 Strategic development

5.2.5 PBI-05204

5.2.5.1 Pre-Clinical study

5.2.5.2 Clinical trials

5.2.6 Uprosertib

5.2.6.1 Clinical trials

5.2.7 PTX-200

5.2.7.1 Clinical trials

5.2.7.2 Clinical trial results

5.2.7.3 Strategic development

5.2.7.4 Designation

5.2.7.5 Patent

5.2.8 ABTL0812

5.2.8.1 Clinical trials

5.2.8.2 Strategic development

5.2.8.3 Designation

5.2.8.4 Grant

5.2.9 Pravitinib

5.2.9.1 Clinical trials

5.2.9.2 Clinical trial results

5.3 Phase I/II

5.3.1 LY2780301

5.3.1.1 Clinical trials

5.3.1.2 Clinical trial results

5.3.2 COTI-2

5.3.2.1 Pre-Clinical

5.3.2.2 Clinical trials

5.3.2.3 Clinical trial results

5.3.2.4 Strategic development

5.3.2.5 Patent

5.3.3 Miransertib

5.3.3.1 Pre-Clinical study

5.3.3.2 Clinical trials

5.3.3.3 Designation

5.3.4 Vofatamab

5.3.4.1 Pre-Clinical study

5.4 Phase I

5.4.1 OB318

5.4.1.1 Clinical trials

5.4.1.2 Strategic development

5.4.2 TAS-117

5.4.3 ISU104

5.4.3.1 Clinical trials

5.4.3.2 Strategic development

5.4.4 M2698

5.4.4.1 Clinical trials

5.4.5 ARQ 751

5.4.5.1 Pre-Clinical study

5.4.5.2 Clinical trials

5.4.5.3 Strategic development

5.5 Pre-Clinical

5.5.1 RES 529

5.5.1.1 Pre-Clinical results

5.5.1.2 Strategic development

5.5.2 EC-70124

5.5.2.1 Pre-Clinical study

5.6 Discovery

5.6.1 eIF4E Inhibitor

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking

7.2 SWOT Analysis

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 F. Hoffman-La-Roche Ltd.

8.1.1 Business Overview

8.1.2 Product and Service Offerings

8.2 Eli Lilly & Company

8.2.1 Business Overview

8.2.2 Product and Service Offerings

8.3 Merck & Co. Inc.

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 Novartis AG

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 Denovo Biopharma LLC

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 Diffusion Pharmaceuticals Inc.

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 Astex Pharmaceuticals

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 ArQule Inc.

8.8.1 Business Overview

8.8.2 Product and Service Offerings

8.9 Cotinga Pharmaceuticals Inc.

8.9.1 Business Overview

8.9.2 Product and Service Offerings

8.10 Oneness Biotech Co. Ltd.

8.10.1 Business Overview

8.10.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

 

TABLE 1 PIPELINE ANALYSIS OF AKT/PKB INHIBITOR, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF IPATASERTIB

TABLE 3 CLINICAL TRIALS OF IPATASERTIB

TABLE 4 CLINICAL RESULTS OF IPATASERTIB

TABLE 5 DESCRIPTION OF ENZASTAURIN

TABLE 6 CLINICAL TRIALS OF ENZASTAURIN

TABLE 7 DESCRIPTION OF CAPIVASERTIB

TABLE 8 CLINICAL TRIALS OF CAPIVASERTIB

TABLE 9 DESCRIPTION OF LY3023414

TABLE 10 CLINICAL TRIALS OF LY3023414

TABLE 11 DESCRIPTION OF MK-2206

TABLE 12 CLINICAL TRIALS OF MK-2206

TABLE 13 DESCRIPTION OF RX-0201

TABLE 14 CLINICAL TRIALS OF RX-0201

TABLE 15 DESCRIPTION OF PBI-05204

TABLE 16 CLINICAL TRIALS OF PBI-05204

TABLE 17 DESCRIPTION OF UPROSERTIB

TABLE 18 CLINICAL TRIALS OF UPROSERTIB

TABLE 19 DESCRIPTION OF PTX-200

TABLE 20 CLINICAL TRIALS OF PTX-200

TABLE 21 DESCRIPTION OF ABTL0812

TABLE 22 CLINICAL TRIALS OF ABTL0812

TABLE 23 DESCRIPTION OF PRAVITINIB

TABLE 24 CLINICAL TRIALS OF PRAVITINIB

TABLE 25 DESCRIPTION OF LY2780301

TABLE 26 CLINICAL TRIALS OF LY2780301

TABLE 27 DESCRIPTION OF COTI-2

TABLE 28 CLINICAL TRIALS OF COTI-2

TABLE 29 DESCRIPTION OF MIRANSERTIB

TABLE 30 CLINICAL TRIALS OF MIRANSERTIB

TABLE 31 DESCRIPTION OF VOFATAMAB

TABLE 32 CLINICAL TRIALS OF VOFATAMAB

TABLE 33 DESCRIPTION OF OB318

TABLE 34 CLINICAL TRIALS OF OB318

TABLE 35 DESCRIPTION OF TAS-117

TABLE 36 DESCRIPTION OF ISU104

TABLE 37 CLINICAL TRIALS OF ISU104

TABLE 38 DESCRIPTION OF M2698

TABLE 39 CLINICAL TRIALS OF M2698

TABLE 40 DESCRIPTION OF ARQ 751

TABLE 41 CLINICAL TRIALS OF ARQ 751

TABLE 42 DESCRIPTION OF RES 529

TABLE 43 DESCRIPTION OF EC-70124

TABLE 44 DESCRIPTION OF EIF4E INHIBITOR

TABLE 45 F. HOFFMAN-LA-ROCHE LTD. – AT A GLANCE

TABLE 46 ELI LILLY & COMPANY – AT A GLANCE

TABLE 47 MERCK & CO. INC. – AT A GLANCE

TABLE 48 NOVARTIS AG – AT A GLANCE

TABLE 49 DENOVO BIOPHARMA LLC – AT A GLANCE

TABLE 50 DIFFUSION PHARMACEUTICALS INC. – AT A GLANCE

TABLE 51 ASTEX PHARMACEUTICALS – AT A GLANCE

TABLE 52 ARQULE INC. – AT A GLANCE

TABLE 53 COTINGA PHARMACEUTICALS INC. – AT A GLANCE

TABLE 54 ONENESS BIOTECH CO. LTD. – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH BY PRIMARY RESPONDANTS

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 4 AKT/PKB INHIBITORS UNDER DEVELOPMENT (2018)

FIG 5 AKT/PKB INHIBITOR PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6 AKT/PKB INHIBITOR PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9 KEY PLAYERS BENCHMARKING

FIG 10 SWOT ANALYSIS